Literature DB >> 32435928

Development and validation of an 18F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer/T cell lymphoma.

Hongxi Wang1, Shengnan Zhao2, Li Li1, Rong Tian3.   

Abstract

OBJECTIVES: To identify an 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics-based model for predicting progression-free survival (PFS) and overall survival (OS) of nasal-type extranodal natural killer/T cell lymphoma (ENKTL).
METHODS: In this retrospective study, a total of 110 ENKTL patients were divided into a training cohort (n = 82) and a validation cohort (n = 28). Forty-one features were extracted from pretreatment PET images of the patients. Least absolute shrinkage and selection operator (LASSO) regression was used to develop the radiomic signatures (R-signatures). A radiomics-based model was built and validated in the two cohorts and compared with a metabolism-based model.
RESULTS: The R-signatures were constructed with moderate predictive ability in the training and validation cohorts (R-signaturePFS: AUC = 0.788 and 0.473; R-signatureOS: AUC = 0.637 and 0.730). For PFS, the radiomics-based model showed better discrimination than the metabolism-based model in the training cohort (C-index = 0.811 vs. 0.751) but poorer discrimination in the validation cohort (C-index = 0.588 vs. 0.693). The calibration of the radiomics-based model was poorer than that of the metabolism-based model (training cohort: p = 0.415 vs. 0.428, validation cohort: p = 0.228 vs. 0.652). For OS, the performance of the radiomics-based model was poorer (training cohort: C-index = 0.818 vs. 0.828, p = 0.853 vs. 0.885; validation cohort: C-index = 0.628 vs. 0.753, p < 0.05 vs. 0.913).
CONCLUSIONS: Radiomic features derived from PET images can predict the outcomes of patients with ENKTL, but the performance of the radiomics-based model was inferior to that of the metabolism-based model. KEY POINTS: • The R-signatures calculated by using 18F-FDG PET radiomic features can predict the survival of patients with ENKTL. • The radiomics-based models integrating the R-signatures and clinical factors achieved good predictive values. • The performance of the radiomics-based model was inferior to that of the metabolism-based model in the two cohorts.

Entities:  

Keywords:  Lymphoma; Positron emission tomography; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 32435928     DOI: 10.1007/s00330-020-06943-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  10 in total

Review 1.  Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors:  Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal:  PET Clin       Date:  2022-01

Review 2.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

3.  Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma.

Authors:  Chong Jiang; Ang Li; Yue Teng; Xiangjun Huang; Chongyang Ding; Jianxin Chen; Jingyan Xu; Zhengyang Zhou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 10.057

Review 4.  Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment.

Authors:  Han Jiang; Ang Li; Zhongyou Ji; Mei Tian; Hong Zhang
Journal:  Mol Imaging Biol       Date:  2022-01-14       Impact factor: 3.484

5.  A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA.

Authors:  Lale Kostakoglu; Federico Dalmasso; Paola Berchialla; Larry A Pierce; Umberto Vitolo; Maurizio Martelli; Laurie H Sehn; Marek Trněný; Tina G Nielsen; Christopher R Bolen; Deniz Sahin; Calvin Lee; Tarec Christoffer El-Galaly; Federico Mattiello; Paul E Kinahan; Stephane Chauvie
Journal:  EJHaem       Date:  2022-03-24

Review 6.  Functional imaging using radiomic features in assessment of lymphoma.

Authors:  Marius E Mayerhoefer; Lale Umutlu; Heiko Schöder
Journal:  Methods       Date:  2020-07-04       Impact factor: 3.608

7.  Development and Validation of a Nomogram Based on 18F-FDG PET/CT Radiomics to Predict the Overall Survival in Adult Hemophagocytic Lymphohistiocytosis.

Authors:  Xu Yang; Jun Liu; Xia Lu; Ying Kan; Wei Wang; Shuxin Zhang; Lei Liu; Hui Zhang; Jixia Li; Jigang Yang
Journal:  Front Med (Lausanne)       Date:  2021-12-22

8.  Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.

Authors:  Yeye Zhou; Jihui Li; Xiaoyi Zhang; Tongtong Jia; Bin Zhang; Na Dai; Shibiao Sang; Shengming Deng
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

9.  Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging?

Authors:  Jie Xiao; Haojun Yu; Xiuli Sui; Yan Hu; Yanyan Cao; Guobing Liu; Yiqiu Zhang; Pengcheng Hu; Ying Wang; Chenwei Li; Baixuan Xu; Hongcheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-29       Impact factor: 9.236

10.  Radiomic analysis for predicting prognosis of colorectal cancer from preoperative 18F-FDG PET/CT.

Authors:  Lilang Lv; Bowen Xin; Yichao Hao; Ziyi Yang; Junyan Xu; Lisheng Wang; Xiuying Wang; Shaoli Song; Xiaomao Guo
Journal:  J Transl Med       Date:  2022-02-02       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.